Business
MaaT Pharma Provides a Business Update and Highlights Key Milestones Expected in 2025
LYON, France, June 19, 2025--MaaT Pharma Provides a Business Update and Highlights Key Milestones Expected in 2025
About this update from Maat Pharma
LYON, France, June 19, 2025 --( BUSINESS WIRE )--Regulatory News: MaaT Pharma (EURONEXT: MAAT – the "Company"), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem Therapies TM (MET) dedicated to enhancing survival for patients with cancer through immune modulation, today provides a business update and highlights its key milestones expected for the second half of 2025. "Following the submission of the Marketing Authorization Application to the EMA for our lead asset, Xervyteg ® , earlier this month, we are excited to advance Xervyteg ® toward commercialization — a potential world first for a microbiota therapeutic in oncology — and are now fully focused on progressing registration activities across Europe", said Hervé Affagard, CEO and co-founder of MaaT Pharma. "This marks a major step in confirming our commitment to address high unmet medical needs and, importantly, it serves as a stepping stone toward international expansion, as we aim to bring our therapies to patients worldwide" Pipeline highlights In Hemato-Oncology Acute Graft-versus-Host Disease (aGvHD) – Xervyteg ® (MaaT013) Allogenic Hematopoietic Stem Cell Transplant (allo-HSCT) - MaaT033 In Immuno-Oncology Xervyteg ® and MaaT033 – Proof-of-Concept trials using the MET-N platform (donor derived conducted as Investigator-Sponsored Trials (ISTs). MaaT034 – Next-generation drug candidates with co-cultured technology (MET-C platform) In Neurodegenerative Diseases As a reminder, the Company’s Annual General Meeting will take place on Friday, June 20, 2025, at 9:30am CET at the Company’s headquarter in France located at 70 avenue Tony Garnier, 69007 Lyon and will also be broadcasted live. A presentation by the management team on recent developments and perspectives will take place from 9:00 to 9:30 a.m. CET, prior to the General Meeting. For more information, please visit the investors section on the Company’s website . --- About MaaT Pharma MaaT Pharma is a leading, late-stage clinical company focused on developing innovative gut microbiome-driven therapies to modulate the immune system and enhance cancer patient survival. Supported by a talented team committed to making a difference for patients worldwide, the Company was founded in 2014 and is based in Lyon, France. As a pioneer, MaaT Pharma is leading the way in bringing the first microbiome-driven immunomodulator in oncology. Using its proprietary pooling and co-cultivation technologies, MaaT Pharma develops high diversity, standardized drug candidates, aiming at extending life of cancer patients. MaaT Pharma has been listed on Euronext Paris (ticker: MAAT) since 2021. Forward-looking Statements All statements other than statements of historical fact included in this press release about future events are subject to (i) change without notice and (ii) factors beyond the Company’s control. These statements may include, without limitation, any statements preceded by, followed by, or including words such as "target," "believe," "expect," "aim", "intend," "may," "anticipate," "estimate," "plan," "project," "will," "can have," "likely," "should," "would," "could" and other words and terms of similar meaning or the negative thereof. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company’s control that could cause the Company’s actual results or performance to be materially different from the expected results or performance expressed or implied by such forward-looking statements. View source version on businesswire.com: https://www.businesswire.com/news/home/20250619859926/en/ Contacts MaaT Pharma – Investor Relations Guilhaume DEBROAS, Ph.D. Head of Investor Relations +33 6 16 48 92 50 [email protected] Rx Communications Group – U.S. Investor Relations Michael Miller Managing Director +1-917-633-6086 [email protected] MaaT Pharma – Media Relations Pauline RICHAUD Senior PR & Corporate Communications Manager +33 6 14 06 45 92 [email protected] Catalytic Agency – U.S. Media Relations Heather Shea Media relations for MaaT Pharma +1 617-286-2013 [email protected]